|

Anti-CD40 Agonist Monoclonal Antibody CDX-1140 Clinical Trials

2 actively recruiting trials across 2 locations

Also known as: Agonist CD40 Antibody CDX-1140, Anti-CD40 Agonistic Monoclonal Antibody CDX-1140, CDX 1140, CDX-1140

Pipeline

Phase 2: 2

Top Sponsors

  • Roswell Park Cancer Institute1
  • National Cancer Institute (NCI)1

Indications

  • Cancer2
  • Recurrent Nasal Cavity Squamous Cell Carcinoma1
  • Recurrent Head and Neck Cutaneous Squamous Cell Carcinoma1
  • Nasal Cavity Squamous Cell Carcinoma1
  • Head and Neck Cutaneous Squamous Cell Carcinoma1

Irvine, California1 trial

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

Phase 2

Buffalo, New York1 trial

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

Roswell Park Cancer Institute

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.